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Inflammatory changes, characterized by an increase in pro-
inflammatory cytokineproduction andup-regulationof the cor-
responding signaling pathways, have been described in the
brains of aged rats and rats treated with the potent immune
modulatory molecule lipopolysaccharide (LPS). These changes
have been coupled with a deficit in long-term potentiation
(LTP) in hippocampus. The evidence suggests that anti-inflam-
matory agents, which attenuate the LPS-induced and age-asso-
ciated increase in hippocampal interleukin-1 (IL-1) concen-
tration, lead to restoration of LTP. Here we report that
atorvastatin, a member of the family of agents that act as inhib-
itors of 3-hydroxy-3-methylglutaryl-CoA reductase, exerts
powerful anti-inflammatory effects in brain and that these
effects are mediated by IL-4 and independent of its cholesterol-
lowering actions. Treatment of rats with atorvastatin increased
IL-4 concentration in hippocampal tissue prepared from LPS-
treated and aged rats and abrogated the age-related and LPS-
induced increases in pro-inflammatory cytokines, interferon-
(IFN) and IL-1, and the accompanying deficit in LTP. The
effect of atorvastatin on the LPS-induced increases in IFN and
IL-1 was absent in tissue prepared from IL-4/ mice. The
increase in IL-1 in LPS-treated and aged rats is associatedwith
increased microglial activation, assessed by analysis of major
histocompatibility complex II expression, and the evidence sug-
gests that IFNmay trigger this activation.We propose that the
primary effect of atorvastatin is to increase IL-4, which antago-
nizes the effects of IFN, the associated increase in microglial
activation, and the subsequent cascade of events.
The adverse effects of inflammation in the brain have been
shown to include down-regulation of synaptic function. One
manifestation of this is a decrease in the ability of rats to sustain
long-termpotentiation (LTP),3 a formof synaptic plasticity that
is considered to be a potential biological substrate for learning
and/or memory. Inflammatory changes, typified by an increase
in concentration of the pro-inflammatory cytokine, interleu-
kin-1 (IL-1), have been observed in aged rats (1, 2) and in rats
treated with lipopolysaccharide (LPS (3, 4)) or -amyloid pep-
tides (A (5)). In each of these conditions, LTP is impaired and,
in some cases, the impairment is abrogated by strategies that
restore IL-1 concentration to the lower values observed in
control conditions (4). A role for IL-4 inmodulating IL-1 pro-
duction has been demonstrated (6), and we have observed that
two treatments with anti-inflammatory properties, the polyun-
saturated fatty acid, eicosapentaenoic acid (6) and rosiglita-
zone,4 abrogate age- and LPS-induced neuroinflammation by
increasing IL-4 concentration in hippocampus. These data
highlight the potential of anti-inflammatory treatments to
restore functional deficits associated with inflammation and
draw an interesting parallel with the observation that the inci-
dence of Alzheimer disease is reduced in individuals undergo-
ing anti-inflammatory treatments for other conditions (7).
It seems likely that the increase in IL-1 concentration in the
brain in inflammatory conditions is derived from activated
microglia, and therefore parallel changes in IL-1 concentra-
tion and microglial activation have been identified in brain of
aged and LPS-treated rats (8). However, the trigger leading to
activation of microglia has not been identified, although results
from several studies have suggested that one of themost potent
activators of microglia in vitro is interferon- (IFN (9–11)).
Recent work has identified anti-inflammatory properties of
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(i.e. statins) that are distinct from their ability to lower choles-
terol. It has been shown that statins reduce A deposition and
inflammatory changes in mouse models of Alzheimer disease
(12–14), block paralysis in chronic and relapsing experimental
autoimmune encephalomyelitis (15), reduce infarct size in
ischemia, and improve neurologic outcome by directly up-reg-
ulating brain endothelial nitric-oxide synthase (16). Statins
have also been shown to decrease symptoms and mortality in
stroke-prone spontaneously hypertensive rats (17).
Because of their reported anti-inflammatory effects, it might
be predicted that statins will counteract the inflammatory
changes induced by age and by LPS treatment. To test this pre-
diction, we investigated the effect of atorvastatin treatment on
the age-related and LPS-induced changes in rat hippocampus.
We report that the age- and LPS-associated microglial activa-
tion, increase in concentrations of IFN and IL-1, and deficit
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in LTP were abrogated in atorvastatin-treated rats. Because
atorvastatin failed to attenuate the LPS-induced increases in
cytokine concentrations in tissue prepared from IL-4/mice,
we propose that the primary action of atorvastatin may be to
trigger production of IL-4 and thereby prevent the IFN-in-
duced microglial activation.
EXPERIMENTAL PROCEDURES
Animals—Twenty-four, 2- to 3-month-old male Wistar rats
(BioResources Unit, Trinity College, Dublin, Ireland), were
used in the first study, and 18 aged (22–24 months) and 12
young (3–4 months) animals (Bantham and Kingman, UK)
were used in the second study. We also used 24 2- to 5-month-
old C57BL/6 (Harlan UK Ltd.) and C57BL/6 IL-4-defective (IL-
4/)mice (B&KUniversal, UK). Ratswere housed in groups of
2–6, and mice were housed singly, under a 12-h light schedule.
Ambient temperature was controlled between 22 and 23 °C,
and animals were maintained under veterinary supervision
throughout the study. These experiments were performed
under a license issued by the Department of Health (Ireland)
and with ethical approval from the local ethical review group.
Atorvastatin Treatment Regimen—Food and water intake
was assessed daily for 1 week, and animals were then randomly
assigned to a control treatment or atorvastatin treatment
group. Atorvastatin (5 and 10 mg/kg/day in the case of rats and
mice, respectively; Lipitor, Pfizer-Parke Davis, Ireland) was
given orally for 3 weeks in the laboratory chow. In the first and
third studies, the control- and atorvastatin-treated groups of
rats and mice were subsequently subdivided into those that
received saline intraperitoneally and those that received LPS
(100 g/kg Escherichia coli serotype 0111.B4, Sigma-Aldrich,
UK) intraperitoneally on the day of the experiment. In the sec-
ond study, young and aged rats were subdivided into control-
and atorvastatin-treated groups, and treatment continued for 8
weeks. Rats and mice were given their daily allowance of food
and monitored to ensure that they received their full daily dose
of atorvastatin. Animals were weighed at intervals throughout
the study to ensure that similar weight changes were occurring
in the different treatment groups. At the end of the treatment
period, mice were killed by cervical dislocation, the brain was
rapidly removed, dissected on ice, sliced (350 350m) using
a McIlwain tissue chopper, and stored in Krebs buffer contain-
ing CaCl2 (1.13 mM) and 10% Me2SO at 80 °C as previously
described (1) until required for analysis. Rats were assessed for
their ability to sustain LTP.
Induction of LTP in Vivo—Young rats were anesthetized by
intraperitoneal injection of urethane (1.5 g/kg), and aged rats
were initially given 1.2 g/kg urethane with further increments
to a maximum of 2.0 g/kg when required. The absence of a
pedal reflex was considered to be an indicator of deep anesthe-
sia. In the case of the experiments in which the effect of atorv-
astatin was assessed on LPS-induced changes, LPS (100 g/kg,
Sigma, UK) or saline was injected intraperitoneally and 3 h later
animals were assessed for their ability to sustain LTP. In some
experiments rats were injected intracerebroventricularly (2.5
mm posterior, and 0.5 mm lateral, to Bregma) with IFN (50
ng/ml, 5l, Chemicon International, Inc.), IL-4 (20 ng/ml, 5l,
R&D Systems, UK) or both, and 30 min later these rats were
assessed for their ability to sustain LTP in perforant path-gran-
ule cell synapses as described previously (1). Briefly, a bipolar-
stimulating electrode and a unipolar-recording electrode were
stereotaxically positioned in the perforant path (4.4 mm lateral
to lambda) and dorsal cell body region of the dentate gyrus (3.9
mm posterior, and 2.5 mm lateral, to Bregma), respectively.
Test shockswere delivered at 30-s intervals, and recorded for 10
min before and 45 min after tetanic stimulation. The stimula-
tion paradigm used involved delivery of 3 trains of stimuli (250
Hz for 200 ms) with an intertrain interval of 30 s, which has
been shown to induce saturable LTP in perforant path-granule
cell synapses in young adult rats (18); this stimulation paradigm
has revealed a deficit in LTP in aged rats.
At the end of the recording period, rats were killed by decap-
itation, the brains were rapidly removed, and the hippocampus
was dissected. One-third of the hippocampus was flash-frozen
in liquid N2 for later analysis of mRNA (see below), and slices
(350 350m) were prepared from the rest of the tissue using
a McIlwain tissue chopper. These slices were stored in Krebs
buffer containing CaCl2 (1.13 mM) and 10% Me2SO at 80 °C
as previously described (1) until required for analysis. Cortical
tissue was similarly prepared and stored for later analysis of
cholesterol.
Analysis of IL-1, IFN-, and IL-4—The concentrations of
IL-1, IFN, and IL-4 were assessed by enzyme-linked immu-
nosorbent assay (R&D Systems, UK) in the stored hippocampal
slices prepared from rats (2). IFN and IL-1 concentrations
were also assessed in tissue prepared from wild-type and
IL-4/ mice. Slices were thawed, rinsed, homogenized, and
equalized for protein (19). For analysis of rat tissue the follow-
ing antibodies were used to coat 96-well plates; 1.0 g/ml goat
anti-rat IL-1 antibody (R&D Systems, UK), or 2.0 g/ml
mouse anti-rat IFN antibody, or 2.0g/mlmouse anti-rat IL-4
antibody (diluted in phosphate-buffered saline, pH 7.3). For
analysis of tissue prepared from mice, 1.25 g/ml goat anti-
mouse IFN antibody (BIOSOURCE,UK) or 4g/ml goat anti-
mouse IL-1 antibody (R&D Systems, UK) were used. Plates
were incubated overnight at room temperature, washed,
blocked, and incubated with standards (0–1000 pg/ml) or sam-
ples for 2 h at room temperature. Wells were washed and incu-
bated with the following antibodies: 350 ng/ml biotinylated
goat anti-rat antibody for IL-1, 150 ng/ml biotinylated goat
anti-rat antibody for IFN, or 50 ng/ml biotinylated goat anti-
rat antibody for IL-4, each diluted in phosphate-buffered saline
containing 1% BSA and 2% normal goat serum, or 100 ng/ml
biotinylated goat anti-mouse IL-1 antibody, and 125 ng/ml
biotinylated goat anti-mouse IFN antibody (R&D Systems,
UK). Horseradish peroxidase-conjugated streptavidin (1:200)
and substrate solution (1:1 mixture of H2O2 and tetramethyl-
benzidine) were added, incubation continued in the dark for
20–30 min, and the reaction was stopped using 1 M H2SO4.
Absorbance was read at 450 nm, and values were corrected for
protein in the case of homogenates and expressed as pico-
grams/mg of protein.
Analysis of Expression of MHCII—We assessed OX6 mRNA
expression as an indicator of MHCII. Total RNA was extracted
from hippocampal tissue using TRI reagent (Sigma), reverse
transcription-PCR was undertaken (5), and cDNA synthesis
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was performed on 1 g of total RNA using oligo(dT) primers
(Superscript reverse transcriptase; Invitrogen Ltd., UK). Equal
amounts of cDNAwere used for PCR amplification for a total of
30 cycles, and the following sequences of primers were used:
upstream 5-CAG TCA CAG AAG GCG TTT ATG-3; down-
stream, 5-TGCAGCATC TGACAGCAGGA-3; and for rat
-actinmRNA expression: upstream, 5-AGAAGAGCTATG
AGC TGC CTG AGG-3; downstream, 5-CTT CTG CAT
CCT GTC AGC GAT GC-3. The cycling conditions were
95 °C for 300 s, 65 °C for 60 s, and 72 °C for 120 s. The reaction
was stopped by a final extension at 72 °C for 10 min. These
primers generated OX-6 PCR products at 245 bp and -actin
PCR products at 250 bp. Equal volumes of PCR product from
each sample were loaded onto 1.5% agarose gels, and bands
were separated by application of 90 V, photographed, and
quantified using densitometry. The target genes were normal-
ized to -actin mRNA expression (i.e. the housekeeping gene).
No change in -actin mRNA was observed with treatment.
Western Immunoblot Analysis of JNK, c-Jun, p38, and NFB—
Phosphorylation of JNK, c-Jun, p38, and NFB was analyzed in
samples prepared from hippocampal tissue as described for
analysis of JNKphosphorylation (20); JNKphosphorylationwas
assessed in nuclear and cytosolic fractions and c-Jun phospho-
rylation, p38, and NFB activation in nuclear fractions only.
The cytosolic fraction was prepared by homogenizing hip-
pocampal slices in lysis buffer (composition in mM: 20 HEPES,
pH 7.4, 10 KCl, 1.5 MgCl2, 1 EDTA, 1 EGTA, 1 dithiothreitol,
0.1 phenylmethylsulfonyl fluoride, containing pepstatin A (5
g/ml), leupeptin (2g/ml), and aprotinin (2g/ml)), incubat-
ing for 20min on ice, and centrifuging (15,000 g for 10min at
4 °C). The supernatant (i.e. cytosolic fraction) was suspended in
sample buffer (Tris-HCl, 150mM, pH6.8; glycerol 10%v/v; SDS,
4% w/v; -mercaptoethanol, 5% v/v; bromphenol blue, 0.002%
w/v) to a final concentration of 300g/ml, boiled for 3min, and
loaded (10 g/lane) onto 10% SDS gels. The nuclear fraction
was prepared by homogenizing hippocampal slices in Krebs
solution containing 2mMCaCl2, incubating for 15min on ice in
permeabilization buffer (composition: 70 mM KCl, 250 mM
sucrose, 137mMNaCl, 4.5 mMNa2HPO4, 1.4 mMKH2PO4, 100
Mphenylmethylsulfonyl fluoride, 10g/ml leupeptin, 2g/ml
aprotinin, 200g/ml digitonin) and centrifuging (600 g for 15
min at 4 °C). The pellet (i.e. nuclear fraction) was resuspended
in sample buffer (Tris-HCl, 150 mM, pH 6.8; glycerol 10% v/v;
SDS, 4% w/v; -mercaptoethanol, 5% v/v; bromphenol blue,
0.002% w/v) to a final concentration of 10 g/ml, boiled for 3
min, and loaded onto 10% SDS gels. All tissue samples were
equalized for protein concentration, and 10-l aliquots (1
mg/ml) were added to sample buffer (5 l; Tris-HCl, 0.5 mM,
pH6.8; glycerol, 10%; SDS, 10%;-mercaptoethanol, 5%; brom-
phenol blue, 0.05% w/v), boiled for 5 min, and loaded onto 10%
SDS gels. Proteins were separated by application of a 30-mA
constant current for 25–30min, transferred onto nitrocellulose
strips (225mA for 75min), and immunoblottedwith the appro-
priate antibody.
To assess JNK activity, proteins were immunoblotted with
an antibody that specifically targets phosphorylated JNK
(1:400 in Tris-buffered saline (TBS)-Tween (0.05% Tween-
20) containing 0.1% BSA; Santa Cruz Biotechnology, Santa
Cruz, CA) for 2 h at room temperature. Immunoreactive
bands were detected using peroxidase-conjugated anti-
mouse IgG (Sigma) and Super Signal chemiluminescence
(Pierce). To assess phosphorylation of c-Jun, nitrocellulose
membranes were blocked in TBS containing 5% BSA over-
night at 4 °C and immunoblotted with a mouse monoclonal
antibody (1:300 dilution in phosphate-buffered saline-
Tween containing 2% nonfat dried milk, Cell Signaling) for
2 h at room temperature. In the case of p38, nitrocellulose
membranes were blocked in 2% BSA in TBS overnight at 4 °C
and immunoblotted with a mouse monoclonal antibody
(1:200 dilution in TBS-Tween containing 0.1% BSA, Sigma)
for 2 h at room temperature. Immunoreactive bands were
detected using peroxidase-conjugated anti-mouse IgG (Sig-
ma-Aldrich) and Super Signal chemiluminescence (Pierce).
In the case of NFB, nitrocellulose membranes were blocked
in 5% BSA in TBS overnight at 4 °C and immunoblotted with
a rabbit monoclonal antibody (1:300 dilution in TBS-Tween
containing 0.1% BSA, Cell Signaling Technology) for 2 h at
room temperature. Immunoreactive bands were detected
using peroxidase-conjugated anti-rabbit IgG (Sigma-Al-
drich) and Super Signal chemiluminescence (Pierce). Blots
were stripped (Reblot Plus, Chemicon) and reprobed with an
anti-actin antibody (Santa Cruz Biotechnology); in the case
of JNK, c-Jun, and NFB, antibodies raised against the
unphosphorylated form were used to confirm equal loading.
Cholesterol Analysis—NMR spectra were recorded at
room temperature on a JEOL ECA600 NMR spectrometer
operating at 600-Hz proton frequency. The spectra were
acquired in the Fourier transformation mode with 32 K data
points, using a 45° pulse width. The residual monodeuter-
ated water signal at 4.7 ppm was suppressed by the appli-
cation of a continuous and selective secondary irradiation
during the relaxation delay. Chemical shifts were referenced
to the residual methanol peak at 3.31 ppm. Spectral assign-
ments were made by reference to data already in the litera-
ture (21, 22). Cholesterol was identified and quantified by its
characteristic C-18 methyl singlet at 0.68 ppm.
Statistical Analysis—Data were analyzed, as appropriate, using
eitherStudent’s t test for independentmeansora two-wayanalysis
of variance (ANOVA) followed by post hoc Student Newman-
Keuls test to determinewhich conditionswere significantly differ-
ent from each other. Data are expressed as means with standard
errors and deemed statistically significant when p 0.05.
RESULTS
Atorvastatin Attenuates LPS-induced Inflammatory Changes—
MHCII mRNA expression and IL-1 concentration were sig-
nificantly increased in hippocampal tissue prepared from LPS-
injected rats, comparedwith controls (*, p 0.05, ANOVA, Fig.
1, a and b); both changeswere attenuated in hippocampal tissue
prepared from atorvastatin-treated rats so that mean values
were similar in tissue prepared from control-treated rats and
LPS-treated rats, which received atorvastatin. Interaction of
IL-1 with its receptor IL-1RI has been shown to trigger
sequential activation of JNK and c-Jun (4, 5), and activation of
p38 andNFB (23), therefore expression of the phosphorylated
forms of these proteins was assessed in hippocampal tissue.
IL-4 in Atorvastatin-associated Neuroprotection
1810 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 4•JANUARY 25, 2008
 by guest, on Decem
ber 16, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
Expression of phosphorylated JNK (pJNK, expressed as a ratio
of pJNK to total JNK in cytosolic and nuclear fractions) and p38
(expressed in a cytosolic fraction as a ratio of phosphorylated
p38 (p-p38) to actin) were significantly increased in tissue pre-
pared from LPS-treated, compared with control-treated,
rats (*, p  0.05, ANOVA, Fig. 1, c and d, and Fig. 2a). These
increaseswere attenuated inLPS-treated rats that received ator-
vastatin so that the mean values in these groups were similar to
those in controls and, in the case of cytosolic pJNK, significantly
reduced compared with the value in tissue prepared from LPS-
treated rats (, p 0.05, ANOVA). Expression of total JNK and
actin was unchanged with treat-
ment. In parallel with these changes,
activation of c-Jun (expressed as a
ratio of c-Jun phosphorylated on
serine 63 or serine 73 to c-Jun) and
NFB (expressed as a ratio of phos-
phorylated NF B to total NFB) in
nuclear fractions obtained from the
same tissue, were significantly
increased in LPS-treated, compared
with control, rats (*, p 0.05; **, p
0.01, ANOVA, Figs. 1e, 1f, and 2b).
These increases were attenuated in
LPS-treated rats that received ator-
vastatin so that the mean values in
these groupswere similar to those in
controls, and, in the case of NFkB,
significantly decreased compared
with the value in tissue prepared
fromLPS-treated rats (, p 0.01,
ANOVA). Expression of unphos-
phorylated NFB was unchanged
with treatment.
Atorvastatin Attenuates the LPS-
induced Inhibition of LTP—It has
been consistently shown that, when
hippocampal IL-1 concentration is
increased, LTP is impaired and that
inhibition of JNK (3) and p38 (23)
antagonizes the LPS-induced inhi-
bition of LTP. The present results
support these observations and
show that, in parallel with the
increases in IL-1 concentration
and JNK and p38 activation, LTP is
impaired in LPS-treated animals.
Thus, high frequency stimulation of
the perforant path led to an imme-
diate and sustained increase in pop-
ulation EPSP slope in control rats,
whereas LTP was markedly attenu-
ated in rats injected with LPS (p 
0.001, ANOVA, Fig. 3a). There was
a significant decrease in the mean
percentage change in population
EPSP slope in the last 10 min of the
experiment compared with the
mean value in the 5 min prior to stimulation in the LPS-treated
group (84.46  0.62), compared with the controls (123.3 
1.16; **, p  0.01, ANOVA, Fig. 3b). Mean population EPSP
slope was significantly decreased in rats that received atorvas-
tatin (109.6  0.86; *, p  0.05, ANOVA, Fig. 3b) compared
with controls, and atorvastatin blocked the inhibitory effect of
LPS on LTP so that the mean percentage change in EPSP slope
in the last 10 min of the experiment was significantly greater in
LPS-treated animals that received atorvastatin (137.0  1.09)
compared with controls (**, p 0.01, ANOVA) or animals that
received LPS (, p 0.01, ANOVA).
0.0
0.5
1.0
1.5
*
- +                    - +      LPS
Control                       Atorvastatin
Ar
bit
ra
ry 
un
its
0
250
500 *
- +                    - +      LPS
Control                       Atorvastatin
IL
-1
β
(p
g/
m
g)
0
20
40
*
+
- +                     - +      LPS
Control                     Atorvastatin
Ar
bi
tra
ry
 u
ni
ts
0
20
40 *
- +                    - +      LPS
Control                       Atorvastatin
Ar
bi
tra
ry
 u
ni
ts
0.0
0.5
1.0
*
- +                    - +      LPS
Control                       Atorvastatin
A
rb
itr
ar
y 
un
its
0.0
0.5
1.0
1.5 *
- +                    - +      LPS
Control                       Atorvastatin
Ar
bi
tra
ry
 u
ni
ts
a.
b.
c.
d.
e.
f.
1         2        3         4
1         2        3        4
p-JNK
JNK
p-c-jun
p-c-jun
c-jun
c-jun
1         2        3        4 1         2        3       4
p-JNK
JNK
1         2        3        4
MHCII
βactin
Ar
bit
ra
ry 
un
its
Ar
bit
ra
ry 
un
its
IL
-1
β
(p
g/
m
g)
IL
-1
β
(p
g/
m
g)
Ar
bi
tra
ry
 u
ni
ts
Ar
bi
tra
ry
 u
ni
ts
FIGURE 1. Atorvastatin blocks the LPS-induced changes in hippocampus. LPS injection (100 g/kg, intra-
peritoneally) significantly increased expression of MHCII mRNA (a), IL-1 concentration (b), JNK activation in
cytosolic (c), andnuclear (d) fractions, andphosphorylationof c-JunonSerine-63 (e) andSerine-73 (f, *,p0.05,
ANOVA). These effectswere blocked in tissue prepared fromanimals treated orallywith atorvastatin (5mg/kg/
day) for 3 weeks (, p  0.05, ANOVA, versus LPS alone). Atorvastatin exerted no significant effect in saline-
treated rats. Data in all cases are expressed as means of five or six observations (S.E.). For c–f, mean arbitrary
values (S.E.) obtained from densitometric analysis are presented, and sample blots are shown (for control-
treated (lane 1), LPS-treated (lane 2), atorvastatin-treated (lane 3), andLPSplus atorvastatin-treated (lane 4) rats;
in all cases blots were stripped and reprobedwith total JNK or total c-Jun to confirm equal loading of proteins.
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Atorvastatin Also Attenuates the LPS-induced Increase in
IFN—These data suggest that LPS-induced microglial activa-
tion may trigger the cascade of events leading to inhibition of
LTP and that atorvastatin exerts its effects, because it down-
regulates microglial activation or the trigger leading to activa-
tion of microglia. Because previous evidence indicated that
IFN triggers activation ofmicroglia in vitro (24) we considered
that it might also trigger the response observed here in vivo.
Mean IFN concentration was significantly increased in tissue
prepared from LPS-treated rats (*, p 0.05, ANOVA, Fig. 4a),
and this was attenuated by atorvastatin so that IFN concen-
trationwas similar in tissue prepared fromLPS-treated rats that
received atorvastatin and in tissue prepared from control-
treated rats.
IL-4 Mediates the Effects of Atorvastatin and Blocks IFN-
induced Changes—It has been reported that atorvastatin can
induce a Th2 response characterized by increased secretion of
anti-inflammatory cytokines like IL-4 (15); because of this and
because we have previously shown that IL-4 inhibits LPS-in-
duced changes in hippocampus (3), we considered that the
action of atorvastatin might be mediated by IL-4. We report
that IL-4 concentration was significantly enhanced in hip-
pocampal tissue prepared from atorvastatin-treated compared
with control-treated rats (*, p 0.05, ANOVA, Fig. 4b) but that
IL-4 concentration was significantly decreased in tissue pre-
pared from LPS-treated rats that did not receive atorvastatin
compared with those that did (, p 0.05, ANOVA, Fig. 4b). If
IL-4 mediates the effects of atorvastatin, then it must be pre-
dicted that atorvastatin will not exert any effect in tissue pre-
pared from IL-4/ mice, and to check this we compared its
effect on LPS-induced changes in these and wild-type mice. In
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NFB. LPS injection (100 g/kg, intraperitoneally) significantly increased
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analysis are presented, and sample blots are shown; in all cases blots were
stripped and reprobed with actin or total NFB to confirm equal loading of
proteins.
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percentage changes in population EPSP slope in the last 10min of the exper-
iment comparedwith themean value in the 5min prior to tetanic stimulation
are shown; data reveal a significant decrease in LPS-treated rats compared
with control rats (**, p  0.01, ANOVA); atorvastatin treatment significantly
attenuated the LPS-induced effect (, p 0.01, ANOVA, versus LPS alone).
MeanEPSP slopewas significantly reduced in saline-treated rats that received
atorvastatin (*, p 0.05, ANOVA, versus saline). The mean value in the last 10
minof theexperimentwas significantly reduced in atorvastatin-treated, com-
paredwith control-treated, rats (*, p 0.05, ANOVA). Values are presented as
means of between five and six observations (S.E.).
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parallel with the findings in rats, IFN and IL-1 were signifi-
cantly increased in tissue prepared from LPS-treated wild-type
mice (*, p 0.05; ***, p 0.001, ANOVA, Fig. 4, c and d), and
atorvastatin significantly attenuated these changes (, p 0.05;
, p  0.01, ANOVA), so that mean cytokine values were
similar in tissue prepared from LPS-treated animals that
received atorvastatin and in control-treated animals. In con-
trast, whereas LPS increased IFN and IL-1, albeit insignifi-
cantly, in samples prepared from IL-4/ mice, there was no
evidence of an effect of atorvastatin in these animals.
If IL-4 mediates the effect of atorvastatin, and if the key LPS-
induced action leading to degenerative change is an increase in
IFN, then it must be predicted that IL-4, like atorvastatin, will
antagonize the effects of IFN. Intracerebroventricular injec-
tion of IFN significantly increased hippocampal MHCII
mRNA expression, IL-1 concentration, and JNK activation
(**, p 0.01, ANOVA, Fig. 5, a–c), and these effects were atten-
uated in tissue prepared from rats treated with IFN and IL-4
(, p 0.05 in the case of MHCII expression and , p 0.01
in the case of JNK activation, ANOVA). Consistent with our
previous findings, the increases in microglial activation, IL-1
concentration, and JNK activation were coupled with a deficit
in LTP. Thus LTP was significantly attenuated in IFN-treated
rats (Fig. 6, a and b); the mean percentage changes in popula-
tion EPSP slope in the last 10min of the experiment (compared
with the mean value in the 5 min prior to stimulation), were
129.9 0.72 in control-treated rats and 86.36 0.73 in IFN-
treated animals (***, p  0.001, ANOVA, Fig. 6b). IL-4 treat-
ment completely abrogated the effect of IFN; the mean per-
centage change in population EPSP slope was 135.1  0.81,
which was not significantly different from that in control-
treated rats, but was significantly greater than the value
observed in rats that received IFN alone (, p  0.001,
ANOVA, Fig. 6b).
Atorvastatin Attenuates the Age-related Inflammatory
Changes and the Deficit in LTP—Previous studies from this
laboratory have identified similarities in signaling events
between LPS-treated rats and aged rats, in particular signaling
events triggered by increased IL-1 concentration (1, 3, 4).
Here we report that there were significant age-related increases
in concentrations of IFN and IL-1 and in MHCII mRNA
expression in hippocampal tissue prepared from aged, com-
pared with young rats (*, p 0.05; **, p 0.01, ANOVA, Fig. 7,
a–c) and that treatment with atorvastatin blocked these age-
related changes so that the values in tissue prepared from hip-
pocampus of aged atorvastatin-treated rats were significantly
decreased compared with those in tissue prepared from aged
rats that did not receive atorvastatin (, p 0.05; , p 0.01,
ANOVA). Although atorvastatin completely reversed the
IFN-induced increases in cytokine concentration, its effect on
MHCII was partial, and, therefore, the mean value in tissue
prepared from aged rats that received atorvastatin was signifi-
cantly greater than in both groups of young rats (*, p  0.05,
ANOVA).
The data show that there was a significant age-related
decrease in IL-4 concentration (*, p  0.05, ANOVA, Fig. 7d)
and that this was significantly attenuated by atorvastatin so that
meanhippocampal IL-4 concentrationwas significantly greater
in tissue prepared from aged rats that received atorvastatin
comparedwith aged control rats (, p 0.05, ANOVA, Fig. 7d).
Importantly the atorvastatin-induced changes were associated
with rescue of the age-related deficit in LTP; LTP was signifi-
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FIGURE 4. Atorvastatin increases hippocampal IL-4 concentration and
attenuates the LPS-induced changes in IFN hippocampal concentra-
tions. a, mean IFN concentration was increased in tissue prepared from
LPS-treated, compared with control-treated, rats (*, p  0.05, ANOVA, n 
8/9); this effect was attenuated in tissue prepared from atorvastatin-treated
rats. b, mean IL-4 concentration was significantly increased with tissue pre-
pared from atorvastatin-treated compared with control-treated, rats (*, p 
0.05, ANOVA); this effect was significantly reduced in tissue prepared from
atorvastatin-treated animals that received LPS (, p  0.05, ANOVA, n  5).
c and d, IFN and IL-1 concentrations were significantly increased in tissue
prepared from LPS-treated wild-type mice (*, p  0.05; ***, p  0.001,
ANOVA), andatorvastatin significantly attenuated these changes (,p0.05;
, p 0.01, ANOVA, versus LPS alone). In contrast, the effect of atorvastatin
(ATV) was absent in tissue prepared from IL-4/mice.
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cantly decreased in aged, compared with young, rats, whereas
LTP in aged rats that received atorvastatinwas similar to that in
young animals. The mean percentage changes in population
EPSP slope in the last 10min of the experiment (comparedwith
the mean value in the 5 min prior to stimulation) were 118.1
0.77, 94.36 0.58, and 133.3 0.38 in young rats, aged control-
treated rats, and aged rats that received atorvastatin, respec-
tively. These values represent a significant difference in aged
control-treated rats compared with young rats (**, p  0.01,
ANOVA, Fig. 7f) and between aged control-treated and aged
atorvastatin-treated rats (, p 0.01, ANOVA, Fig. 7f). EPSP
slope in young, atorvastatin-treated rats was also decreased
(123.7  0.39) compared with the value in young, control-
treated rats (**, p 0.01, ANOVA, Fig. 7f).
Atorvastatin Does Not Exert Any Effect on Cholesterol Con-
centration in Brain—We assessed cholesterol concentration in
samples of cortical tissue prepared from control- and LPS-
treated young rats that did/did not receive atorvastatin and in
young and aged, control-treated, and atorvastatin-treated, rats.
Cholesterol was similar in control-treated and LPS-treated rats
(37.16 0.3 and 36.37 0.67 mol%), and atorvastatin exerted
no significant effect on cholesterol (37.16  0.2 and 36.57 
0.41 in control-treated and LPS-treated rats, respectively). In
contrast cholesterol was significantly increased in tissue pre-
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FIGURE 5. IL-4 attenuates IFN-induced changes in hippocampus. a, intrac-
erebroventricular injectionof IFN (5l; 50ng/ml) significantly increasedexpres-
sion ofMHCIImRNA (**, p 0.01, ANOVA, n 5), and this effect was blocked by
co-injection with IL-4 (5 l; 20 ng/ml; , p  0.05, ANOVA). b and c, the IFN-
induced increases in IL-1 concentration (b) and JNK activation (c) in hippocam-
pal tissue prepared from IFN-treated rats were significantly greater than in
saline-treated rats (**, p  0.01, ANOVA), whereas the values in hippocampal
tissueprepared fromIFNand IL-4co-injectedratsweresimilar to those insaline-
treated controls and, in the case of JNK activation, significantly decreased com-
pared with the value observed in tissue prepared from rats treated with IFN
alone(,p0.01,ANOVA).Sampleblots indicatingchanges inphosphorylated
JNK in hippocampal tissue prepared from control (lane 1), IFN- (lane 2), and
IFNIL-4- (lane 3)-treated rats are presented. Values are presented asmeans of
between five and six observations (S.E.).
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FIGURE 6. IL-4 abrogates the IFN-induced inhibition of LTP. a, intracere-
broventricular injection of IL-4 (5 l; 20 ng/ml) abrogated the deficit in LTP
induced by IFN (5 l; 50 ng/ml) so that the population EPSP slope in
response to tetanic stimulation in the rats treated with IFNwas significantly
reduced compared with that in rats treated with saline, or IL-4 and IFN.
Sample recordings in the5minprior to tetanic stimulation (pre) and in the last
5minof theexperiment (post) aregiven for control-treated, IFN-treated, and
IFNIL-4-treated rats. b, analysis of themean percentage changes in popu-
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IL-4 in Atorvastatin-associated Neuroprotection
1814 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 4•JANUARY 25, 2008
 by guest, on Decem
ber 16, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
pared from aged (39.97 0.34), compared with young (37.89
0.41), rats (p 0.01, ANOVA), but therewas no evidence of any
effect of atorvastatin treatment in either age group (38.19 
0.20 and 40.48  0.43 in young and aged atorvastatin-treated
rats, respectively).
DISCUSSION
We set out to establish whether atorvastatin, which is known
to possess anti-inflammatory properties, might modulate the
neuro-inflammatory changes induced by LPS and age in the rat
hippocampus that lead to impairment of LTP. We report that
microglial activation, IFN, and IL-1 were increased in hip-
pocampal tissue prepared from aged and LPS-treated rats and
that these changes were accompanied by inhibition of LTP.We
hypothesize that the primary action of atorvastatin is to
increase IL-4 and that this prevents the IFN-induced micro-
glial activation, which triggers the cascade of events. This
hypothesis is supported by the find-
ing that atorvastatin fails to attenu-
ate the LPS-induced increases in
IFN and IL-1 in tissue prepared
from IL-4/mice.
Our data describe an age-related,
as well as an LPS-induced, increase
in IL-1 concentration in the hip-
pocampus paralleled by increased
microglial activation, which is con-
sistent with the view that these cells
are the likely source of IL-1 (6,
25, 26). We considered that IFN
might trigger the activation of
microglia in the hippocampus of
LPS-treated and aged rats, because
it a potent activator of microglia in
vitro (24, 27). We found that hip-
pocampal concentration of IFN
was increased in parallel with the
increase in microglial activation in
the hippocampal tissue prepared
from LPS-treated and aged rats,
whereas these changes were also
observed following intracerebrov-
entricular injection of IFN. Recent
evidence from studies in aged rats
has indicated that the impairment
in LTP is associated, not only with
increased IL-1, butwith an array of
changes in pro-inflammatory and
anti-inflammatory cytokines, (26,
27); specifically, an inverse correla-
tion between hippocampal concen-
trations of IL-1 and IL-4 has been
identified as being critical in deter-
mining the ability of aged rats to
sustain LTP (28). Significantly, we
have previously reported that
increasing hippocampal IL-4 con-
centration reverses the age-related
andLPS-induceddeficits in LTP and that intracerebroventricu-
lar injection of IL-4 partly attenuates the age-related deficit in
LTP (6, 29).
We addressed the possible role of IL-4 here by asking
whether the atorvastatin-induced modulation of IL-1 was
coupled with a change in IL-4, and our data show that IL-4
concentrationwas indeed increased in atorvastatin-treated rats
that received LPS and that atorvastatin treatment was associ-
ated with a reversal of the age-related decrease in IL-4. We
demonstrate that IL-4 attenuates the IFN-triggered increases
in MHCII expression and IL-1 concentration and, in parallel,
antagonizes the IFN-induced inhibition of LTP. This antago-
nistic effect of IL-4 on IFN-induced changes indicates that the
atorvastatin-induced increase in IL-4 inhibits the cascade of
events triggered by the age- and LPS-induced increase in the
hippocampal concentration of IFN and the subsequentmicro-
glial activation. Moreover it is in agreement with the previous
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FIGURE 7.Atorvastatin abrogates age-related changes in the rat hippocampus.Mean IFN concentration
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(d) was significantly decreased in hippocampal tissue prepared from aged, compared with young, rats (*, p
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compelling evidence indicating that IL-4 potently blocks the
effects of IFN, including the IFN-induced activation of CD40
in a microglial cell line (24).
If the action of atorvastatin is mediated through IL-4, then it
follows that atorvastatin will not have the same anti-inflamma-
tory effects in IL-4/ mice, and therefore we compared its
ability to attenuate the LPS-induced changes in wild-type and
IL-4/ mice. Intraperitoneal injection of LPS increased both
IFN and IL-1 in brain tissue prepared from wild-type mice,
and these effects were attenuated in the atorvastatin-treated
mice. In contrast, atorvastatin exerted no effect on LPS-in-
duced changes in tissue prepared from IL-4/ mice, demon-
strating that the effect of atorvastatin is IL-4-dependent. Con-
sistent with these data, Youssef and colleagues (15) suggested
that the beneficial effects of atorvastatin in attenuating the det-
rimental changes associated with experimental autoimmune
encephalomyelitis were achieved by up-regulating release of
Th2-derived cytokines, which include IL-4, from splenocytes.
Although the data presented here suggest that the atorvasta-
tin-induced increase in IL-4 is the key factor in decreasing
microglial activation, there is a lack of concordance in the liter-
ature regarding the effect of statins onmicroglial activation. On
the one hand certain statins have been reported to induce
inflammation, for instance lovastatin has been shown to
increase IL-1 concentration in brain tissue of transgenic
mice, which overexpress human amyloid precursor protein
(30), and TNF concentration in cultured hippocampal slices
(13). Similarly, cerivastatin and fluvastatin have been reported
to up-regulate IL-1- and IFN-induced changes in smooth
muscle (31, 32) and hepatoma cells (32). In contrast, simvasta-
tin and lovastatin block the A-induced increase in IL-1 pro-
duction inmonocytes and BV2 cells (33) and the IFN-induced
increase in release of TNF, IL-1 and IL-6 in cultured micro-
glia (34). We have recently reported a beneficial effect of ator-
vastatin treatment in vivo against A-induced increases in
microglial activation and IL-1 concentration (35). This anti-
inflammatory role is supported by a large body of evidence indi-
cating that certain statins are protective in ischemia (36–39)
and experimental autoimmune encephalomyelitis (see Ref. 40)
in which the degenerative effects are attributed, at least in part,
to inflammation and microglial activation.
We demonstrate that the effects of LPS and atorvastatin on
microglial activation and IL-1 concentration were mirrored
by changes in activation of JNK and c-Jun and in activation of
p38 and NFB. The importance of these signaling cascades in
modulating LTP has been highlighted by the demonstration
that the LPS-induced inhibition of LTP was blocked by inhibi-
tors of JNK, p38, and NFB (3, 23). To our knowledge there are
no data showing that statins can attenuate LPS-induced and/or
IL-1-mediated signaling cascades in brain in vivo and few data
documenting a modulatory effect in vitro (41). In contrast, sev-
eral studies have revealed that statins block stimulus-induced
activation of JNK and/or c-Jun in myocytes (42), Chinese ham-
ster ovary cells (43), and macrophages (44), whereas a similar
antagonistic effect on stimulus-induced activation of p38 and
NFB in monocytes (45), vascular endothelial cells (46), and
macrophages (47, 48) has been reported. A significant finding
of this study is that atorvastatin treatment abrogates the inflam-
matory and signaling changes in rat hippocampus which we
believe are mediated by increased IL-1 concentration. The
evidence suggests that a key action relies on its ability to mod-
ulate the IFN-induced microglial activation in LPS-treated
and in aged rats. One downstream consequence of this is that
atorvastatin restores LTP in both groups of rats. Results from
epidemiological studies indicate a beneficial effect of statin
therapy on cognition (49–53), which is consistent with the
present data. However, it has also been suggested that statins
may exert a negative effect on cognitive function (54), although
a recent report indicated that atorvastatin (10 mg/day) had no
such effect (55). We have previously reported a small but sta-
tistically significant atorvastatin-induced decrease in LTP in
young rats following a 3-week treatment period (35), and the
data presented here concur with this, but treatment for 8 weeks
did not modulate LTP.
One of the key issues raised regarding the potential effects of
statins in the central nervous system relates to their ability to
cross the blood-brain barrier (56). Some researchers have
asserted that atorvastatin is lipophilic (57, 58), whereas others
suggest it is not (59).Wedetected small amounts of atorvastatin
(30 pg) in the brains of atorvastatin-treated animals (data not
shown), which suggests that it can enter the brain, but whether
this is a result of blood-brain barrier breakdown following LPS
challenge, facilitated transport via atorvastatin transporters, or
simple diffusion remains to be determined. Whether a statin
that can cross the blood-brain barrier is advantageous or not is
a question that remains, and it must be concluded that the
effect of statins is dependent on the specific statin, the tissue
under investigation, and the stimulus upon which the modula-
tory effects are analyzed.
Importantly, althoughwe observed an age-related increase in
cholesterol concentration in brain tissue (though LPS exerted
no effect), atorvastatin failed to modulate brain cholesterol
concentration. We conclude that the effects of atorvastatin
described here are unrelated to its well described cholesterol-
lowering action. The data suggest that its beneficial effects
derive from its ability tomaintainmicroglia in a quiescent state,
and in particular, from its ability to increase IL-4.
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